Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2016 - 2025)

Ultragenyx Pharmaceutical has reported Interest & Investment Income over the past 10 years, most recently at $6.5 million for Q4 2025.

  • Quarterly Interest & Investment Income fell 35.17% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, down 32.43% year-over-year, with the annual reading at $25.0 million for FY2025, 32.43% down from the prior year.
  • Interest & Investment Income was $6.5 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $5.9 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $10.7 million in Q3 2024 and troughed at $408000.0 in Q3 2021.
  • The 5-year median for Interest & Investment Income is $5.9 million (2023), against an average of $5.1 million.
  • Year-over-year, Interest & Investment Income plummeted 78.11% in 2021 and then skyrocketed 1308.64% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $440000.0 in 2021, then skyrocketed by 1308.64% to $6.2 million in 2022, then surged by 43.03% to $8.9 million in 2023, then rose by 13.3% to $10.0 million in 2024, then tumbled by 35.17% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Interest & Investment Income are $6.5 million (Q4 2025), $5.9 million (Q3 2025), and $5.8 million (Q2 2025).